The Hot CPI Report May Be the Medicine the Market Needed
A warm inflation number lets the market price in the worst case for the Fed, and biotech is already acting like it has washed out. Here’s my plan.
Upside, Downside Movers in the Morning
Upside
– $GIXI +135.0% (autonomous robots begin delivering blood and bone marrow at a major hospital, expanding an existing chemotherapy-logistics deployment)
– $CCC +10.5% (GTCR and Elliott are reportedly in advanced acquisition talks, with a deal potentially coming this week)
– $MEDS +7.0% (Humana adds the ChemoFx gynecologic-cancer assay to a Medicaid coverage policy)
– $IREN +5.5% (Anthropic is reportedly the previously undisclosed customer behind a multiyear AI-cloud services agreement)
– $BIIB +2.5% (JPMorgan upgrades to Overweight, citing an increasingly compelling clinical-catalyst path)
– $BFLY +1.5% (Canaccord initiates coverage with a Buy rating)
Downside
– $WFF -15.5% (gives back part of Friday’s nearly 500% speculative surge, with no fresh company catalyst identified)
– $QUCY -13.5% (launches an at-the-market equity program allowing up to $100 million of share sales)
– $MU -2.5%, $MRVL -2.0%, $INTC -1.5% (chip stocks weaken as advanced-memory competition and concerns over AI spending weigh on the sector)
This Is a Good Time to Make a Stock-Picking List
As biotech is getting hit and we’re seeing ETF-driven selling, I smell opportunity for sharp traders.
Walmart Sends Stagflation Warning With Harsh Report
As the market quickly forgets a significant Treasury buyback, the retail giant offered a concerning economic update.